Secondary analysis (substudy) of the ASPREE RCT in 124 adults aged 70+: low-dose aspirin showed no effect vs placebo on central age-related hearing decline (cortical auditory responses, speech-in-noise perception) over up to 5 years, though hearing deteriorated in both groups.
Secondary analysisn = 124
Rance et al. Low-Dose Aspirin and Central Presbycusis: A Substudy of the ASPREE Randomized Clinical Trial